| CARGO Therapeutics Provides Corporate Update |
- Development of CRG-023 and allogeneic platform suspended; further reduction in force (RIF) of approximately 90% to preserve cash and maximize shareholder value - - CARGO had cash, cash equivalents and marketable securities of $368.1 million as of December 31, 2024 - - Anup Radhakrishnan appointed as interim CEO to pursue reverse merger or other business combination - SAN CARLOS, Calif., March 18, 2025 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (Nasdaq: CRGX) today provided an update regarding its ongoing evaluation of strategic options following the discontinuation of FIRCE-1, a Phase 2 study of firicabtagene autoleucel (firi-cel). |
globenewswire.com |
2025-03-18 18:05:00 |
Czytaj oryginał (ang.) |
| An Investigation Has Commenced on Behalf of CARGO Therapeutics, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your CRGX Losses. |
NEW YORK, NY / ACCESS Newswire / March 4, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of CARGO Therapeutics, Inc. ("CARGO Therapeutics, Inc.") (NASDAQ:CRGX) concerning possible violations of federal securities laws. On January 29, 2025, CARGO announced in a press release that it "has elected to discontinue FIRCE-1, a Phase 2 clinical study of firi-cel for patients with large B-cell lymphoma (LBCL) whose disease relapsed or was refractory (R/R) to CD19 CAR T-cell therapy. |
accessnewswire.com |
2025-03-04 09:30:00 |
Czytaj oryginał (ang.) |
| Lost Money on CARGO Therapeutics, Inc.(CRGX)? Contact Levi & Korsinsky Regarding an Ongoing Investigation |
NEW YORK, NY / ACCESS Newswire / March 2, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of CARGO Therapeutics, Inc. ("CARGO Therapeutics, Inc.") (NASDAQ:CRGX) concerning possible violations of federal securities laws. On January 29, 2025, CARGO announced in a press release that it "has elected to discontinue FIRCE-1, a Phase 2 clinical study of firi-cel for patients with large B-cell lymphoma (LBCL) whose disease relapsed or was refractory (R/R) to CD19 CAR T-cell therapy. |
accessnewswire.com |
2025-03-02 13:13:00 |
Czytaj oryginał (ang.) |
| An Investigation Has Been Launched Into CARGO Therapeutics, Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm |
LOS ANGELES, CA / ACCESS Newswire / March 2, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CARGO Therapeutics, Inc. ("CARGO" or "the Company") (NASDAQ:CRGX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accessnewswire.com |
2025-03-02 13:00:00 |
Czytaj oryginał (ang.) |
| CARGO Therapeutics, Inc. (CRGX) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights |
NEW YORK, NY / ACCESS Newswire / March 1, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of CARGO Therapeutics, Inc. ("CARGO Therapeutics, Inc.") (NASDAQ:CRGX) concerning possible violations of federal securities laws. On January 29, 2025, CARGO announced in a press release that it "has elected to discontinue FIRCE-1, a Phase 2 clinical study of firi-cel for patients with large B-cell lymphoma (LBCL) whose disease relapsed or was refractory (R/R) to CD19 CAR T-cell therapy. |
accessnewswire.com |
2025-03-01 20:01:00 |
Czytaj oryginał (ang.) |
| The Schall Law Firm Invites Shareholders With Losses In CARGO Therapeutics, Inc. To Join A Securities Fraud Investigation |
LOS ANGELES, CA / ACCESS Newswire / March 1, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CARGO Therapeutics, Inc. ("CARGO" or "the Company") (NASDAQ:CRGX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accessnewswire.com |
2025-03-01 13:00:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CARGO Therapeutics, Inc - CRGX |
NEW YORK CITY, NY / ACCESS Newswire / March 1, 2025 / Pomerantz LLP is investigating claims on behalf of investors of CARGO Therapeutics, Inc. ("Cargo" or the "Company") (NASDAQ:CRGX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-03-01 12:00:00 |
Czytaj oryginał (ang.) |
| Levi & Korsinsky Reminds Shareholders of an Investigation into CARGO Therapeutics, Inc. (CRGX) Regarding Potential Securities Fraud Allegations |
NEW YORK, NY / ACCESS Newswire / February 28, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of CARGO Therapeutics, Inc. ("CARGO Therapeutics, Inc.") (NASDAQ:CRGX) concerning possible violations of federal securities laws. On January 29, 2025, CARGO announced in a press release that it "has elected to discontinue FIRCE-1, a Phase 2 clinical study of firi-cel for patients with large B-cell lymphoma (LBCL) whose disease relapsed or was refractory (R/R) to CD19 CAR T-cell therapy. |
accessnewswire.com |
2025-02-28 13:30:00 |
Czytaj oryginał (ang.) |
| An Investigation Has Been Launched Into CARGO Therapeutics, Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm |
LOS ANGELES, CA / ACCESS Newswire / February 28, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CARGO Therapeutics, Inc. ("CARGO" or "the Company") (NASDAQ:CRGX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accessnewswire.com |
2025-02-28 13:00:00 |
Czytaj oryginał (ang.) |
| CRGX ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by CARGO Therapeutics, Inc. |
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of CARGO Therapeutics, Inc. ("CARGO Therapeutics, Inc.") (NASDAQ:CRGX) concerning possible violations of federal securities laws. On January 29, 2025, CARGO announced in a press release that it "has elected to discontinue FIRCE-1, a Phase 2 clinical study of firi-cel for patients with large B-cell lymphoma (LBCL) whose disease relapsed or was refractory (R/R) to CD19 CAR T-cell therapy. |
accessnewswire.com |
2025-02-27 14:00:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CARGO Therapeutics, Inc - CRGX |
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / Pomerantz LLP is investigating claims on behalf of investors of CARGO Therapeutics, Inc. ("Cargo" or the "Company") (NASDAQ:CRGX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-02-27 13:30:00 |
Czytaj oryginał (ang.) |
| Levi & Korsinsky Reminds Shareholders of an Investigation into CARGO Therapeutics, Inc. (CRGX) Regarding Potential Securities Fraud Allegations |
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of CARGO Therapeutics, Inc. ("CARGO Therapeutics, Inc.") (NASDAQ:CRGX) concerning possible violations of federal securities laws. On January 29, 2025, CARGO announced in a press release that it "has elected to discontinue FIRCE-1, a Phase 2 clinical study of firi-cel for patients with large B-cell lymphoma (LBCL) whose disease relapsed or was refractory (R/R) to CD19 CAR T-cell therapy. |
accessnewswire.com |
2025-02-27 12:15:00 |
Czytaj oryginał (ang.) |
| The Schall Law Firm Invites Shareholders With Losses In CARGO Therapeutics, Inc. To Join A Securities Fraud Investigation |
LOS ANGELES, CA / ACCESS Newswire / February 27, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CARGO Therapeutics, Inc. ("CARGO" or "the Company") (NASDAQ:CRGX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accessnewswire.com |
2025-02-27 12:00:00 |
Czytaj oryginał (ang.) |
| CARGO Therapeutics, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - CRGX |
NEW YORK, NY / ACCESS Newswire / February 26, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of CARGO Therapeutics, Inc. ("CARGO Therapeutics, Inc.") (NASDAQ:CRGX) concerning possible violations of federal securities laws. On January 29, 2025, CARGO announced in a press release that it "has elected to discontinue FIRCE-1, a Phase 2 clinical study of firi-cel for patients with large B-cell lymphoma (LBCL) whose disease relapsed or was refractory (R/R) to CD19 CAR T-cell therapy. |
accessnewswire.com |
2025-02-26 12:30:00 |
Czytaj oryginał (ang.) |
| CARGO Therapeutics, Inc. Being Investigated on Behalf of CARGO Therapeutics, Inc. Investors. Contact Levi & Korsinsky For Details. |
NEW YORK, NY / ACCESS Newswire / February 25, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of CARGO Therapeutics, Inc. ("CARGO Therapeutics, Inc.") (NASDAQ:CRGX) concerning possible violations of federal securities laws. On January 29, 2025, CARGO announced in a press release that it "has elected to discontinue FIRCE-1, a Phase 2 clinical study of firi-cel for patients with large B-cell lymphoma (LBCL) whose disease relapsed or was refractory (R/R) to CD19 CAR T-cell therapy. |
accessnewswire.com |
2025-02-25 19:05:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CARGO Therapeutics, Inc - CRGX |
NEW YORK , Feb. 25, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of CARGO Therapeutics, Inc. ("Cargo" or the "Company") (NASDAQ: CRGX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
prnewswire.com |
2025-02-25 18:38:00 |
Czytaj oryginał (ang.) |
| Levi & Korsinsky Reminds CARGO Therapeutics, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - CRGX |
NEW YORK, NY / ACCESS Newswire / February 25, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of CARGO Therapeutics, Inc. ("CARGO Therapeutics, Inc.") (NASDAQ:CRGX) concerning possible violations of federal securities laws. On January 29, 2025, CARGO announced in a press release that it "has elected to discontinue FIRCE-1, a Phase 2 clinical study of firi-cel for patients with large B-cell lymphoma (LBCL) whose disease relapsed or was refractory (R/R) to CD19 CAR T-cell therapy. |
accessnewswire.com |
2025-02-25 12:30:00 |
Czytaj oryginał (ang.) |
| The Schall Law Firm Invites Shareholders With Losses In CARGO Therapeutics, Inc. To Join A Securities Fraud Investigation |
LOS ANGELES, CA / ACCESS Newswire / February 25, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CARGO Therapeutics, Inc. ("CARGO" or "the Company") (NASDAQ:CRGX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accessnewswire.com |
2025-02-25 12:00:00 |
Czytaj oryginał (ang.) |
| CRGX ALERT - Levi & Korsinsky Has Commenced an Investigation on Behalf of CARGO Therapeutics, Inc. Shareholders Who Lost Money |
NEW YORK, NY / ACCESS Newswire / February 24, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of CARGO Therapeutics, Inc. ("CARGO Therapeutics, Inc.") (NASDAQ:CRGX) concerning possible violations of federal securities laws. On January 29, 2025, CARGO announced in a press release that it "has elected to discontinue FIRCE-1, a Phase 2 clinical study of firi-cel for patients with large B-cell lymphoma (LBCL) whose disease relapsed or was refractory (R/R) to CD19 CAR T-cell therapy. |
accessnewswire.com |
2025-02-24 12:30:00 |
Czytaj oryginał (ang.) |
| CRGX ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by CARGO Therapeutics, Inc. |
NEW YORK, NY / ACCESS Newswire / February 23, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of CARGO Therapeutics, Inc. ("CARGO Therapeutics, Inc.") (NASDAQ:CRGX) concerning possible violations of federal securities laws. On January 29, 2025, CARGO announced in a press release that it "has elected to discontinue FIRCE-1, a Phase 2 clinical study of firi-cel for patients with large B-cell lymphoma (LBCL) whose disease relapsed or was refractory (R/R) to CD19 CAR T-cell therapy. |
accessnewswire.com |
2025-02-23 12:19:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CARGO Therapeutics, Inc - CRGX |
NEW YORK CITY, NY / ACCESS Newswire / February 23, 2025 / Pomerantz LLP is investigating claims on behalf of investors of CARGO Therapeutics, Inc. ("Cargo" or the "Company") (NASDAQ:CRGX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-02-23 12:00:00 |
Czytaj oryginał (ang.) |
| Levi & Korsinsky Reminds CARGO Therapeutics, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - CRGX |
NEW YORK, NY / ACCESS Newswire / February 22, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of CARGO Therapeutics, Inc. ("CARGO Therapeutics, Inc.") (NASDAQ:CRGX) concerning possible violations of federal securities laws. On January 29, 2025, CARGO announced in a press release that it "has elected to discontinue FIRCE-1, a Phase 2 clinical study of firi-cel for patients with large B-cell lymphoma (LBCL) whose disease relapsed or was refractory (R/R) to CD19 CAR T-cell therapy. |
accessnewswire.com |
2025-02-22 20:01:00 |
Czytaj oryginał (ang.) |
| An Investigation Has Been Launched Into CARGO Therapeutics, Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm |
LOS ANGELES, CA / ACCESS Newswire / February 22, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CARGO Therapeutics, Inc. ("CARGO" or "the Company") (NASDAQ:CRGX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accessnewswire.com |
2025-02-22 12:00:00 |
Czytaj oryginał (ang.) |
| Investors who Lost Money on CARGO Therapeutics, Inc. should contact Levi & Korsinsky about an ongoing investigation - CRGX |
NEW YORK, NY / ACCESS Newswire / February 21, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of CARGO Therapeutics, Inc. ("CARGO Therapeutics, Inc.") (NASDAQ:CRGX) concerning possible violations of federal securities laws. On January 29, 2025, CARGO announced in a press release that it "has elected to discontinue FIRCE-1, a Phase 2 clinical study of firi-cel for patients with large B-cell lymphoma (LBCL) whose disease relapsed or was refractory (R/R) to CD19 CAR T-cell therapy. |
accessnewswire.com |
2025-02-21 13:30:00 |
Czytaj oryginał (ang.) |
| The Schall Law Firm Invites Shareholders With Losses In CARGO Therapeutics, Inc. To Join A Securities Fraud Investigation |
LOS ANGELES, CA / ACCESS Newswire / February 21, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CARGO Therapeutics, Inc. ("CARGO" or "the Company") (NASDAQ:CRGX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accessnewswire.com |
2025-02-21 13:00:00 |
Czytaj oryginał (ang.) |
| Lost Money on CARGO Therapeutics, Inc. (CRGX)? Contact Levi & Korsinsky Regarding an Ongoing Investigation |
NEW YORK, NY / ACCESS Newswire / February 21, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of CARGO Therapeutics, Inc. ("CARGO Therapeutics, Inc.") (NASDAQ:CRGX) concerning possible violations of federal securities laws. On January 29, 2025, CARGO announced in a press release that it "has elected to discontinue FIRCE-1, a Phase 2 clinical study of firi-cel for patients with large B-cell lymphoma (LBCL) whose disease relapsed or was refractory (R/R) to CD19 CAR T-cell therapy. |
accessnewswire.com |
2025-02-21 12:30:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CARGO Therapeutics, Inc - CRGX |
NEW YORK, NY / ACCESS Newswire / February 21, 2025 / Pomerantz LLP is investigating claims on behalf of investors of CARGO Therapeutics, Inc. ("Cargo" or the "Company") (NASDAQ:CRGX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-02-21 12:00:00 |
Czytaj oryginał (ang.) |
| Lost Money on CARGO Therapeutics, Inc. (CRGX)? Contact Levi & Korsinsky Regarding an Ongoing Investigation |
NEW YORK, NY / ACCESS Newswire / February 20, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of CARGO Therapeutics, Inc. ("CARGO Therapeutics, Inc.") (NASDAQ:CRGX) concerning possible violations of federal securities laws. On January 29, 2025, CARGO announced in a press release that it "has elected to discontinue FIRCE-1, a Phase 2 clinical study of firi-cel for patients with large B-cell lymphoma (LBCL) whose disease relapsed or was refractory (R/R) to CD19 CAR T-cell therapy. |
accessnewswire.com |
2025-02-20 13:45:00 |
Czytaj oryginał (ang.) |
| CARGO Therapeutics, Inc. Is Being Investigated For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm |
LOS ANGELES, CA / ACCESS Newswire / February 20, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CARGO Therapeutics, Inc. ("CARGO" or "the Company") (NASDAQ:CRGX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accessnewswire.com |
2025-02-20 13:00:00 |
Czytaj oryginał (ang.) |
| CARGO Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference |
SAN CARLOS, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. |
globenewswire.com |
2024-12-17 10:00:00 |
Czytaj oryginał (ang.) |
| Down -14.13% in 4 Weeks, Here's Why CARGO Therapeutics, Inc. (CRGX) Looks Ripe for a Turnaround |
CARGO Therapeutics, Inc. (CRGX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. |
zacks.com |
2024-12-16 21:36:08 |
Czytaj oryginał (ang.) |
| Bears are Losing Control Over CARGO Therapeutics, Inc. (CRGX), Here's Why It's a 'Buy' Now |
CARGO Therapeutics, Inc. (CRGX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term. |
zacks.com |
2024-12-12 12:55:22 |
Czytaj oryginał (ang.) |
| CARGO Therapeutics to Participate in Upcoming Investor Conferences |
SAN CARLOS, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. |
globenewswire.com |
2024-11-05 18:05:00 |
Czytaj oryginał (ang.) |
| CARGO Therapeutics Announces ASH 2024 Abstract on CRG-023, a Tri-specific CAR T, Highlighting Innovative Construct Design and Durable Anti-B-Cell Lymphoma Activity |
CARGO Therapeutics Announces ASH 2024 Abstract on CRG-023, a Tri-specific CAR T, Highlighting Innovative Construct Design and Durable Anti-B-Cell Lymphoma |
globenewswire.com |
2024-11-05 11:23:00 |
Czytaj oryginał (ang.) |
| Why Cargo Therapeutics Stock Rocketed Nearly 20% Higher This Week |
The cancer-focused biotech published its second-quarter results. Its loss was much narrower than analysts had expected. |
fool.com |
2024-08-16 22:50:46 |
Czytaj oryginał (ang.) |
| CARGO Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update |
- All sites activated with 38 patients dosed in the potentially pivotal Phase 2 clinical study, FIRCE-1 of firicabtagene autoleucel ( firi-cel) - - Completed $110 million private placement equity financing, extending cash runway through 2026 - SAN CARLOS, Calif., Aug. 12, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. |
globenewswire.com |
2024-08-12 20:05:00 |
Czytaj oryginał (ang.) |
| CARGO Therapeutics Adds Experienced Biopharma Executive to Board of Directors with the Appointment of Jane Pritchett Henderson as Independent Director |
CARGO Therapeutics Adds Experienced Biopharma Executive to Board of Directors with the Appointment of Jane Pritchett Henderson as Independent Director |
globenewswire.com |
2024-06-04 20:05:00 |
Czytaj oryginał (ang.) |
| Undiscovered Stocks on the Verge of a Breakout: 3 Names to Know Now |
Many investors steer clear of limelight stocks. These ideas might already be overvalued and often aren't the breakout stocks that can deliver significant returns. |
investorplace.com |
2024-05-30 10:00:00 |
Czytaj oryginał (ang.) |
| CARGO Therapeutics to Participate in Upcoming Investor Conferences |
SAN CARLOS, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced that the company will be participating in the following investor conferences. |
globenewswire.com |
2024-05-28 12:05:00 |
Czytaj oryginał (ang.) |
| CARGO Therapeutics Announces $110.0 Million Private Placement Equity Financing |
– Financing includes participation from new and existing investors – – Supports BLA preparation for potentially pivotal Phase 2 study, FIRCE-1 of firicabtagene autoleucel (firi-cel) (CRG-022) and IND-enabling studies for CRG-023 – – Extends cash runway through 2026 – SAN CARLOS, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (Nasdaq: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced that it has entered into a securities purchase agreement for a private investment in public equity financing that is expected to result in gross proceeds of approximately $110.0 million, before deducting placement agent fees and other expenses. |
globenewswire.com |
2024-05-28 12:00:00 |
Czytaj oryginał (ang.) |
| What Makes CARGO Therapeutics, Inc. (CRGX) a New Buy Stock |
CARGO Therapeutics, Inc. (CRGX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
zacks.com |
2024-05-22 17:01:24 |
Czytaj oryginał (ang.) |
| Wall Street Analysts See a 56.26% Upside in CARGO Therapeutics, Inc. (CRGX): Can the Stock Really Move This High? |
The consensus price target hints at a 56.3% upside potential for CARGO Therapeutics, Inc. (CRGX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
zacks.com |
2024-05-22 14:56:09 |
Czytaj oryginał (ang.) |
| CARGO Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update |
- 26 sites activated and over 20 patients dosed in the potentially pivotal Phase 2 clinical study, FIRCE-1 of firicabtagene autoleucel ( firi-cel) (CRG-022); Currently on-track for interim results expected in 1H25 - - Independent Data Monitoring Committee (IDMC) recommended continuation of FIRCE-1 without modifications - - Ongoing follow-up from the Stanford Phase 1 study for firi-cel 1 to be presented at the 2024 European Hematology Association (EHA) Congress, highlighting median overall survival of 25.7 months and favorable safety profile at the dose level selected for CARGO's Phase 2 Study - SAN CARLOS, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ: CRGX) , a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today reported financial results for the first quarter ended March 31, 2024 and provided a business update. |
globenewswire.com |
2024-05-14 20:05:00 |
Czytaj oryginał (ang.) |
| CARGO Therapeutics Names Kapil Dhingra, M.B.B.S., to Board of Directors |
– Appointment adds oncology and cell therapy clinical development expertise to Board as Company continues late-stage development of its lead CAR T-cell therapy candidate, firi-cel (CRG-022) – – Appointment adds oncology and cell therapy clinical development expertise to Board as Company continues late-stage development of its lead CAR T-cell therapy candidate, firi-cel (CRG-022) – |
globenewswire.com |
2024-04-15 20:05:00 |
Czytaj oryginał (ang.) |
| CARGO Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update |
– Potentially pivotal Phase 2 clinical study FIRCE-1 of firicabtagene autoleucel (CRG-022) is rapidly recruiting with 20 sites open to date; interim results expected 1H 2025 – SAN MATEO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (Nasdaq: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today provided a business update and reported financial results for the quarter and year ending December 31, 2023. |
globenewswire.com |
2024-03-21 18:05:00 |
Czytaj oryginał (ang.) |
| CARGO Therapeutics to Participate in the 44th Annual Cowen Healthcare Conference |
CARGO Therapeutics announced that the company will participate in the 44th Annual Cowen Healthcare Conference, taking place March 4-6, 2024, in Boston, MA. |
globenewswire.com |
2024-02-29 18:01:00 |
Czytaj oryginał (ang.) |
| IPO watch 2024: Which new stocks will hit the market? |
Among 2023 IPOs, one of the top performers was RayzeBio Inc. NASDAQ: RYZB, a biotech that's out of play now because it's being acquired by Bristol Myers Squibb Co. NYSE: BMY. |
marketbeat.com |
2024-01-08 09:03:12 |
Czytaj oryginał (ang.) |
| CARGO Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference |
SAN MATEO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced that the company will participate in the 42nd Annual J.P. Morgan Healthcare Conference, taking place January 8-11, 2024, in San Francisco, California. |
globenewswire.com |
2024-01-03 10:05:00 |
Czytaj oryginał (ang.) |
| CARGO Therapeutics Reports Business Updates and Third Quarter 2023 Results |
SAN MATEO, Calif., Dec. 13, 2023 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (Nasdaq: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today reported business updates and its financial results for the third quarter ended September 30, 2023. |
globenewswire.com |
2023-12-13 18:05:00 |
Czytaj oryginał (ang.) |